DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
ranitidine — - 1 Brent Wisner - 1 Wisner Baum - 1 Zantac - 1 drugmaker Boehringer - 1 Boehringer - 1 Sanofi - 1 Ludwig Burger - 1
Top related locs:
U.S Britain Delaware France's Sanofi FRANKFURT United States Boehringer
Top related orgs:
GSK - 2 Pfizer - 2 GlaxoSmithKline - 1 Stevenage - 1 Delaware State Court - 1 France's - 1 Germany's - 1 Sanofi - 1

Search resuls for: "France's Sanofi"


4 mentions found


☆ Pharma giant GSK plunges 9% after U.S. court allows scientific testimony in Zantac lawsuits
  + stars: | 2024-06-03 | by ( Jenni Reid | ) www.cnbc.com   time to read: +1 min
Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. LONDON — Shares of British pharmaceuticals giant GSK plunged 9% Monday, after a U.S. court ruled that scientific evidence could be presented in a stack of lawsuits relating to the discontinued heartburn drug Zantac. The Delaware State Court late on Friday ruled that plaintiffs' expert witnesses could testify in the roughly 75,000 cases alleging the once-popular drug ranitidine — sold under the brand name Zantac in the U.S. — may cause cancer. The companies involved deny there is a scientific consensus that the drug can be linked to any later development of cancers. In a statement Friday, GSK said it disagreed with the latest Delaware ruling and would immediately seek an appeal.
Persons: ranitidine —, Brent Wisner, Wisner Baum, Zantac Organizations: GlaxoSmithKline, Stevenage, GSK, Delaware State Court, France's, Pfizer, Germany's Locations: Britain, Delaware, U.S, France's Sanofi
☆ Sanofi says arbitration court rejects Boehringer's Zantac claims
  + stars: | 2023-06-20 | by ( Ludwig Burger | ) www.reuters.com   time to read: +1 min
FRANKFURT, June 20 (Reuters) - Sanofi (SASY.PA) said on Tuesday that the International Chamber of Commerce rejected rival drugmaker Boehringer Ingelheim's (BI) claims to be indemnified by Sanofi in cancer lawsuits linked to heartburn drug Zantac in the United States. Shares in France's Sanofi, which added that the decision cannot be appealed, gained 2.4% shortly after the 0700 GMT market open, reaching a three-week high. Sanofi and Boehringer had sought arbitration to determine whether liability in lawsuits was transferred to the French group after it acquired the marketing rights from Boehringer in a 2017 deal. Sanofi reiterated that it regarded its defence of the underlying litigation as very strong. "There is no reliable scientific evidence that Zantac causes the alleged injuries in the cases brought against GSK, Pfizer, BI, Sanofi, and others in the U.S. litigation," the company said.
Persons: drugmaker Boehringer, Boehringer, Sanofi, Ludwig Burger, Kirsten Donovan, Emma Rumney Organizations: Sanofi, International Chamber of Commerce, GSK, Pfizer, BI, Thomson Locations: FRANKFURT, United States, Boehringer, U.S
☆ Sanofi hones in on type 1 diabetes in $2.9 bln Provention Bio deal
  + stars: | 2023-03-13 | by ( Ludwig Burger Dina Kartit | Ludwig Burger | Dina Kartit | ) www.reuters.com   time to read: +2 min
March 13 (Reuters) - France's Sanofi SA (SASY.PA) on Monday agreed to acquire Provention Bio Inc <PRVB.O> for $2.9 billion to bolster its work on a U.S.-approved type 1 diabetes therapy and strengthen its drug pipeline following development setbacks. The deal builds on an existing co-promotion agreement between the two companies, and would give the French drugmaker full ownership of the drug, Tzield, Sanofi said, adding it expects to complete the acquisition in the second quarter of 2023. While growth in asthma and eczema drug Dupixent is boosting Sanofi's sales, investors have criticised its drug development pipeline as weak. Sanofi, the maker of long acting insulin products Toujeo and Lantus for type 2 diabetes, in 2019 quit further type 2 diabetes drug development. Chief Executive Officer Paul Hudson said last month the company saw great promise in type 1 diabetes drug development and reaffirmed his commitment to steer clear of further work on type 2 diabetes and obesity.
☆ France's Sanofi to acquire US-based Provention Bio for $2.9 bln
  + stars: | 2023-03-13 | by ( Dina Kartit | ) www.reuters.com   time to read: +1 min
March 13 (Reuters) - France's Sanofi (SASY.PA) said on Monday it has entered into a deal to acquire U.S.-based biopharmaceutical company Provention Bio in a transaction worth $2.9 billion, or $25.00 per share in cash. This transaction builds on an existing co-promotion deal between Sanofi and Provention Bio to provide TZIELD to patients in need, said the French firm. "Provention Bio also brings certain pipeline assets in early development in immune-mediated diseases," added the group. Sanofi said it expects to complete the acquisition in the second quarter of 2023. Reporting by Dina Kartit; Editing by Kim CoghillOur Standards: The Thomson Reuters Trust Principles.
0 next >>
Total: 4